-+ 0.00%
-+ 0.00%
-+ 0.00%

Dianthus Q1 FY26 net loss widens 38.37% to $40.8 million

PUBT·05/05/2026 20:05:13
Listen to the news
Dianthus Q1 FY26 net loss widens 38.37% to $40.8 million
  • Dianthus Therapeutics posted Q1 net loss of USD 40.8 million, widening from USD 29.5 million a year earlier; loss per share widened to USD 0.85 from USD 0.82.
  • Revenue fell to USD 463,000 from USD 1.16 million; R&D expense climbed to USD 34.5 million from USD 27 million.
  • G&A expense rose to USD 12.5 million from USD 7.3 million; cash, cash equivalents and investments totaled about USD 1.2 billion at March 31, 2026, with expected runway into 2030.
  • CAPTIVATE CIDP study reached an early GO decision in March 2026 after 20 confirmed responders with fewer than 40 planned participants completing open-label Part A; CAPTIVATE Part B top-line guidance expected by year-end 2026.
  • Phase 3 EMERGE trial in generalized myasthenia gravis on track to start mid-2026 with top-line results anticipated in 2H’28; Phase 2 MoMeNtum trial in MMN expects top-line results in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dianthus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605051601PRIMZONEFULLFEED9713463) on May 05, 2026, and is solely responsible for the information contained therein.